Bone cancers

Dorfman, Howard D.; Czerniak, Bogdan

doi:10.1002/1097-0142(19950101)75:1+<203::aid-cncr2820751308>3.0.co;2-v

Cited by 545 publications

(402 citation statements)

References 19 publications

Supporting

Mentioning

385

Contrasting

Unclassified

Order By: Relevance

“…It was originally reported that males were affected with osteosarcoma more frequently than females 1, 15, 16, 17. However, recent reports suggested that the osteosarcoma incidence may be equal in both sexes 18, 19.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased survival of patients aged 0‐29 years with osteosarcoma: A period analysis, 1984‐2013

Sun

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

PurposeOsteosarcoma is the most common primary malignancy of bone, and typically occurs among children and adolescence. This study aims to evaluate treatment outcomes among children, adolescents and young adults with osteosarcoma over the three decades by the changes in the long‐term relative survival.MethodsOsteosarcoma incidence and relative survival data from Surveillance, Epidemiology, and End Results (SEER) registries during 1984‐2013 were analyzed. The survival differences over three decades, age, sex, race, and socioeconomic status (SES) were assessed by comparing Kaplan‐Meier curves.ResultsThe overall incidence of osteosarcoma kept relatively stable with 0.4 per 100 000 in the three decades with the peak incidence occurring in the aged 10‐19 group. The 10‐year relative survival rate (RSR) increased from 57.7% to 61.0% in the three decades, with the greatest increase in the aged 0‐9 group from 48.2% to 65.7%. The 10‐year RSR improved from 54.1% to 61.5% in males, and from 62.4% to 63.0% in females, respectively, in the three decades. Furthermore, survival dramatically improved from 30% to 60% in the high‐poverty group over the three decades.ConclusionThis study demonstrated that the overall incidence of osteosarcoma remained stable, with an improvement in survival in the three decades. The improved survival was greater in males than in females in the three decades. Furthermore, the survival significantly increased in high‐poverty group, which was attributed to increasing improved health care system and patients with low finance can also have access to receiving effective and consistent treatment without distinction.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Osteosarcoma, the most common primary malignancy of bone, typically occurs among children and adolescence 1. For young patients, it can occur in any bone with the major sites in long bone, especially in the distal femur, proximal tibia, and proximal humerus 2, 3.…”

Section: Introductionmentioning

confidence: 99%

Increased survival of patients aged 0‐29 years with osteosarcoma: A period analysis, 1984‐2013

Sun

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The overall 5-year survival rate is 41.2%. 1,2 Moreover, the prognosis is poor for patients who have had a relapse and for patients with large primary tumors or metastatic disease at presentation. Therefore, new strategies are needed to improve the survival rates.…”

mentioning

confidence: 99%

Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16

et al. 2002

View full text Add to dashboard Cite

This study determined the effect of Ad -E1A gene therapy in vivo. TC71 cells ( 2Â10 6 ) injected subcutaneously into nude mice resulted in tumor development ( 1 -3 mm ) 6 days later. Animals were then treated with Ad -E1A or Ad --gal ( 5Â10 9 plaque -forming units ) by intratumoral injection twice weekly for 2 weeks. Animals received 8 mg / kg VP -16 given by intraperitoneal injection daily for 5 days following the first week of treatment with Ad -E1A or Ad --gal. Control animals received no therapy or VP -16 only after tumor cells were injected. When tumors exceeded 2Â2 cm, the mice were sacrificed and the tumors underwent histologic and immunohistochemical analysis. Tumors from mice treated with Ad -E1A plus VP -16 were 9.6 -fold smaller than those treated with VP -16 alone and 6.3 -fold smaller than those treated with Ad -E1A alone. HER2 / neu p185 protein expression decreased in all tumors that received Ad -E1A therapy. TUNEL fluorescence staining revealed more apoptosis in the tumors from animals treated with Ad -E1A plus VP -16 than in those from animals treated with Ad -E1A alone, Ad --gal plus VP -16, or VP -16 alone. These data demonstrated that Ad -E1A gene therapy down -regulated HER2 / neu expression, increased tumor cell apoptosis induced by VP -16, and enhanced tumor cell sensitivity to VP -16. Ad -E1A may have potential in the treatment of relapsed drug -resistant Ewing's sarcoma. Cancer Gene Therapy ( 2002 ) 9, 407 -413 DOI: 10.1038 / sj / cgt / 7700449Keywords: Ewing's sarcoma; Ad -E1A; gene therapy; VP -16 E wing's sarcoma is the second most common primary malignant bone tumor in children and young adults and has a high potential for metastasizing to the lungs, bones, and bone marrow. Most patients with Ewing's sarcoma die from lung and bone metastases. The overall 5-year survival rate is 41.2%. 1,2 Moreover, the prognosis is poor for patients who have had a relapse and for patients with large primary tumors or metastatic disease at presentation. Therefore, new strategies are needed to improve the survival rates. The HER2/neu oncogene encodes a 185 -kDa human epidermal growth factor receptor-2 transmembrane protein ( p185 ) with intrinsic tyrosine kinase activity. Overexpression of HER2 /neu was found in approximately 30% of human breast and ovarian cancers. 3,4 Enhanced expression of HER2 /neu increased the tumorigenicity and metastatic potential of human ovarian and lung cancer cells. Clinical studies indicated that overexpression of HER2/neu correlated with poor prognosis, shorter patient survival, and chemoresistance. 5,6 We previously demonstrated that TC71 human Ewing's sarcoma cells overexpress HER2/neu. Thus, HER2/ neu may also play a role in the poor disease-free survival rate associated with multiagent chemotherapy in this disease. The adenovirus type 5 early region 1A (E1A ) gene is a wellknown transcriptional factor. This gene inhibits HER2 /neu expression in both rodent and human breast cancer and ovarian cancer cells through the HER2 /neu promoter and with the involvement of the H...

show abstract

“…Primary angiosarcoma of bone is extremely rare and accounts for less than 1% of all angiosarcomas [2,5,7,15]. Dorfman and Czerniak [4] reported only 36 (1.4%) of 2627 primary bone sarcomas were classified as angiosarcomas. These tumors usually occur in long tubular bones and much less frequently in the ribs, pelvis, and vertebrae.…”

Section: Discussion and Treatmentmentioning

confidence: 99%

Orthopaedic · Radiology · Pathology Conference: Left Hip Pain in a 62-year-old Man

Zhao

Fan

2009

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

A 62-year-old man was referred for dull pain of the anterolateral side of his left hip with limited motion for 2 months duration. The pain radiated to the left knee, became worse after long periods of walking or standing, and was not relieved with common analgesics. The pain gradually worsened, and began awakening him at night. He had no history of previous trauma or hip disease. During these 2 months, his body weight decreased by approximately 10 kg. He had no fever, chill, or night sweats.On physical examination, the patient had deep tenderness in the left groin and over the greater trochanter and pain in the left hip when striking the left heel in the straight leg position. There was no swelling, deformity, varicosity, or redness. Sensation was normal, and skin temperature was a bit higher than that of the right hip. The range of motion was decreased: flexion-extension, 75°to -5°; internal-external rotation, 15°to -20°; abduction-adduction, 15°to -25°; however, motion of the left knee and ankle was normal.Laboratory studies, including complete blood count, erythrocyte sedimentation rate, serum chemistries, and carcinoma markers were unremarkable. Plain radiographs ( Fig. 1) and computed tomography (CT) scans of the left hip and pelvis (Fig. 2) were obtained.Based on the history, physical findings, and imaging studies, what is the differential diagnosis? Imaging InterpretationAnteroposterior plain radiographs of the pelvis showed irregularly expansive, loculated lytic bone destruction, especially the medial cortex, with surrounding sclerosis and internal septation and scattered internal calcification in the metaphysis of the left femur and femoral head (Fig. 1), but no periosteal reaction or soft tissue extension was present. CT scans showed a large osteolytic lesion with calcifications and mixed density in the femoral head and intertrochanteric region with erosion of its medial cortex with marked thinning and destruction of the cortex posteromedially and thickening anteriorly. Some swelling of the soft tissue also was seen (Fig. 2). CT scans of the chest did not show any obvious metastasis. Technetium 99 bone scintigraphy showed the lesion was localized in the proximal part of the left femur.

show abstract

Bone cancers

Cited by 545 publications

References 19 publications

Increased survival of patients aged 0‐29 years with osteosarcoma: A period analysis, 1984‐2013

Increased survival of patients aged 0‐29 years with osteosarcoma: A period analysis, 1984‐2013

Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16

Orthopaedic · Radiology · Pathology Conference: Left Hip Pain in a 62-year-old Man

Contact Info

Product

Resources

About